newsfilter
← Latest News
GlobeNewswire·

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

--ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a